You just read:

Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

News provided by

Astellas Pharma Inc.

Sep 14, 2017, 05:00 ET